– USA, CA – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced the appointment of David Happel as CEO, replacing Dr. George Kemble (Ph.D.) transitioning to executive chairman of the board of directors.
“We are pleased to welcome Dave as our new CEO. He brings a strong track record of developing and executing corporate business strategies, raising private and public capital, negotiating M&A transactions, scaling operations, and commercializing products,” said Board Chair, Dr. Beth Seidenberg. “As Sagimet anticipates moving forward to late-stage clinical trials with our lead program, denifanstat, Dave’s experience will be instrumental to the company’s growth. We are fortunate to benefit from George’s continued contributions and expertise in his new role as the board’s executive chairman.”
About David Happel
David Happel brings extensive industry experience, from biotech start-ups to large pharmaceutical companies. He was most recently president and CEO of Cognoa, a pediatric behavioral health company developing AI-based technologies for developmental and behavioral health conditions, including the first FDA-authorized diagnostic aid, Canvas Dx, for autism. Cognoa was named a Fierce MedTech 2021 winner. Happel was previously CEO of Chrono Therapeutics and has held several executive and commercial positions at Horizon Therapeutics, Raptor Pharmaceuticals, Dynavax Technologies, and Chiron.
David Happel has a BA in chemistry from Indiana University and an MBA from Indiana State University.
About Sagimet
Sagimet is a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways in diseases such as nonalcoholic steatohepatitis, certain cancers, and acne. Sagimet compounds are designed to inhibit fatty acid synthase, an enzyme involved in producing fatty acids generally used for energy storage. In NASH, the activity of the FASN enzyme is upregulated, resulting in excess accumulation of liver fat, inflammation, and fibrosis. FASN dysregulation has also been implicated in multiple cancers with lipogenic phenotypes
For more information: https://sagimet.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.